The Protective Role of Etoricoxib Against Diethylnitrosamine/2-acetylaminofluorene-Induced Hepatocarcinogenesis in Wistar Rats: The Impact ofNF-κB/COX-2/PGE2 Signaling / Gaber Ali, Hany Omar, Fatema Hersi, Amira Abo-Youssef, Osama Ahmed, Wafaa Mohamed
Background: Liver cancer ranks as the 7th and 5th leading cause of cancer morbidityworldwide in men and women, respectively. Hepatocellular Carcinoma (HCC) is the most commontype of liver cancer and is associated with an increasing global burden of Nonalcoholic Fatty LiverDisease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Objective: The present study aimed to investigate the possible chemopreventive effect of etoricoxibon diethylnitrosamine (DENA) and 2-acetylaminofluorene (2AAF)-induced HCC in male Wistarrats. Methods: HCC was induced by DENA (150 mg/kg/week; i.p) for 2 weeks, then 2AAF (20 mg/kg;p.o) every other day for three successive weeks. Etoricoxib (0.6 mg/kg, p.o.) was given to DENA/2AAF-administered rats for 20 weeks. Results: Etoricoxib significantly suppressed alpha-fetoprotein (AFP) and carbohydrate antigen19-9 (CA19.9) as liver tumor biomarkers. It also decreased serum aspartate aminotransferase(AST), alanine aminotransferase (ALT), and total bilirubin levels while increased serum albuminlevels. Besides, it alleviated DENA/2AAF-induced histopathological abrasions and inflammatorycell infiltration. Furthermore, etoricoxib showed a potent antioxidant effect, supported by a significantlipid peroxide reduction and elevation in superoxide dismutase activity and GSH content. Inaddition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta(IL-1β), tumor necrosis factor α (TNFα), nuclear Factor-kappa B (NF-κB), phosphorylated nuclearFactor-kappa B (p-NF-κB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2). Conclusion: In conclusion, the current results proved that etoricoxib possesses an anticarcinogeniceffect via its antioxidant, anti-inflammatory, and modulation of NF-κB/COX-2/PGE2 signaling.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Current molecular pharmacology - 15(2022), 1, Seite 11 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ali, Gaber [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (11 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL011168218 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011168218 | ||
| 003 | DE-627 | ||
| 005 | 20231128145923.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230613s2022 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL011168218 | ||
| 035 | |a (KFL)prod_DARH_.3324D8EF9F628D3933BFF354B8D3496F3ABC6CCB | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Ali, Gaber |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Protective Role of Etoricoxib Against Diethylnitrosamine/2-acetylaminofluorene-Induced Hepatocarcinogenesis in Wistar Rats: The Impact ofNF-κB/COX-2/PGE2 Signaling |c Gaber Ali, Hany Omar, Fatema Hersi, Amira Abo-Youssef, Osama Ahmed, Wafaa Mohamed |
| 264 | 1 | |c 2022 | |
| 300 | |a 1 Online-Ressource (11 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Liver cancer ranks as the 7th and 5th leading cause of cancer morbidityworldwide in men and women, respectively. Hepatocellular Carcinoma (HCC) is the most commontype of liver cancer and is associated with an increasing global burden of Nonalcoholic Fatty LiverDisease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Objective: The present study aimed to investigate the possible chemopreventive effect of etoricoxibon diethylnitrosamine (DENA) and 2-acetylaminofluorene (2AAF)-induced HCC in male Wistarrats. Methods: HCC was induced by DENA (150 mg/kg/week; i.p) for 2 weeks, then 2AAF (20 mg/kg;p.o) every other day for three successive weeks. Etoricoxib (0.6 mg/kg, p.o.) was given to DENA/2AAF-administered rats for 20 weeks. Results: Etoricoxib significantly suppressed alpha-fetoprotein (AFP) and carbohydrate antigen19-9 (CA19.9) as liver tumor biomarkers. It also decreased serum aspartate aminotransferase(AST), alanine aminotransferase (ALT), and total bilirubin levels while increased serum albuminlevels. Besides, it alleviated DENA/2AAF-induced histopathological abrasions and inflammatorycell infiltration. Furthermore, etoricoxib showed a potent antioxidant effect, supported by a significantlipid peroxide reduction and elevation in superoxide dismutase activity and GSH content. Inaddition, Etoricoxib significantly down-regulated the protein expression of interleukin 1 beta(IL-1β), tumor necrosis factor α (TNFα), nuclear Factor-kappa B (NF-κB), phosphorylated nuclearFactor-kappa B (p-NF-κB), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2). Conclusion: In conclusion, the current results proved that etoricoxib possesses an anticarcinogeniceffect via its antioxidant, anti-inflammatory, and modulation of NF-κB/COX-2/PGE2 signaling | ||
| 700 | 1 | |a Omar, Hany |e verfasserin |4 aut | |
| 700 | 1 | |a Hersi, Fatema |e verfasserin |4 aut | |
| 700 | 1 | |a Abo-Youssef, Amira |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Osama |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Wafaa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current molecular pharmacology |d Sharjah : Bentham, 2008 |g 15(2022), 1, Seite 11 |h Online-Ressource |w (DE-627)KFL000006564 |w (DE-600)2433118-1 |w (DE-576)306836815 |x 1874-4702 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:1 |g pages:11 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1874-4672&volume=15&issue=1&spage=252 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_DARH_03 | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 1 |h 11 | ||